01—Abstract
Summary
Summary of the 8-K filed June 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc held its 2026 Annual General Meeting of Shareholders on June 4, 2026.
Shareholders present or represented by proxy held 508,180,103 Class A and Class B ordinary shares, voting as a single class, which the filing states represented 88.08%a of the combined voting power entitled to vote and constituted a quorum. The filing reports the results of ten proposals, each described in the company's definitive proxy statement filed April 10, 2026. All nine director nominees were elected to serve until the 2027 Annual General Meeting.
Each received more votes For than Against, though the against votes ranged from 128,998 for Elizabeth Weatherman to 54,472,087 for Vlad Coric, M.D. Shareholders also approved the non-binding advisory say-on-pay proposal (476,044,602 For, 11,067,486 Against, 747,086 Abstain), the U.K. Annual Report and Accounts, the U.K. directors' remuneration report, and the re-appointment of Ernst & Young as U.K. statutory auditor.
Ernst & Young LLP was also ratified as the independent registered public accounting firm, with 506,307,829 votes For and 832,217 Against. Shareholders approved the terms of share repurchase agreements and counterparties (474,475,427 For, 12,499,628 Against), and authorized the Board to allot shares (469,111,384 For, 18,568,396 Against).
The authority to allot shares without pre-emption rights drew the most opposition of the non-director items, at 445,653,078 For and 42,016,406 Against. The filing was signed by Arthur McGivern, EVP, General Counsel & Investments.
02—Key points
Key Highlights
- Annual Meeting held June 4, 2026, with 508,180,103 shares present or represented, equal to 88.08% of combined voting power and a quorum.
- All nine director nominees were elected to serve until the 2027 Annual General Meeting, including Pablo Legorreta, Ted Love, M.D., Bonnie Bassler, Ph.D., Vlad Coric, M.D., Catherine Engelbert, Carole Ho, M.D., David Hodgson, Gregory Norden, and Elizabeth Weatherman.
- Non-binding say-on-pay proposal passed with 476,044,602 For and 11,067,486 Against.
- Ernst & Young LLP was ratified as independent registered public accounting firm with 506,307,829 For and 832,217 Against.
- Share repurchase agreement terms and counterparties were approved with 474,475,427 For and 12,499,628 Against.
- Authority to allot shares was approved with 469,111,384 For and 18,568,396 Against, while the authority to allot shares without pre-emption rights received 445,653,078 For and 42,016,406 Against.
- Vlad Coric, M.D. received the highest number of Against votes among director nominees, at 54,472,087.
03—Questions
Frequently Asked Questions
How many shares participated in the 2026 Annual General Meeting?
508,180,103 Class A and Class B ordinary shares, voting as a single class, were present or represented by proxy. The filing states this represented 88.08% of the combined voting power entitled to vote and constituted a quorum.
Were all director nominees elected?
Yes. All nine nominees were elected by separate ordinary resolutions to serve until the 2027 Annual General Meeting. Each received more For votes than Against votes. Vlad Coric, M.D. had the most Against votes at 54,472,087.
How did shareholders vote on executive compensation?
In the non-binding advisory vote on named executive officer compensation, shareholders cast 476,044,602 For votes, 11,067,486 Against votes, and 747,086 Abstain votes, with 20,320,929 broker non-votes.
Which proposals received the most opposition?
Among the non-director proposals, the authority to allot shares without rights of pre-emption received 42,016,406 Against votes, the largest against count of those proposals. The authority to allot shares received 18,568,396 Against votes, and the share repurchase agreement terms received 12,499,628 Against votes.
Who is the auditor, and was it approved?
Ernst & Young LLP was ratified as the independent registered public accounting firm, with 506,307,829 For, 832,217 Against, and 1,040,057 Abstain votes. Ernst & Young was also re-appointed as U.K. statutory auditor, with 506,752,136 For and 384,952 Against votes.
04—Continue